FRUZAQLA® (fruquintinib) efficacy

Consistent efficacy proven across 2 robust clinical trials.​1-3

Beyond a single study, the FRUZAQLA clinical profile was established across 2 phase 3 trials. FRESCO and FRESCO-2, involving more than 1,100 patients, demonstrated consistent efficacy and a well-established safety profile.1-3 Overall survival was the primary endpoint in both trials, with additional measures including progression-free survival, objective response rate, disease control rate, duration of response, and safety.1,3 Patients were randomized (2:1) to receive FRUZAQLA 5 mg orally once daily for the first 21 days of each 28-day cycle plus BSC or placebo + BSC.1

Check out the results from FRESCO and FRESCO-2.

BSC=best supportive care.

FRESCO STUDY DESIGN

FRESCO was a single-country,* multicenter, randomized, double-blind, placebo-controlled phase 3 study1,2

FRESCO clinical trial design studying FRUZAQLA® + BSC vs placebo + BSC.

Inclusion criteria1,2

  • Aged 18-75
  • ECOG PS 0‑1
  • Progression during or after prior treatment with fluoropyrimidine‑, oxaliplatin‑, or irinotecan‑based chemotherapy
  • No prior treatment with VEGFR inhibitor

Stratification2

  • Prior VEGF inhibitor therapy (yes vs no)
  • K-RAS mutational status (wild type vs mutant)
More than 1100 patients were studied across 2 phase 3 studies, FRESCO and FRESCO-2.

*The FRESCO study was conducted in China.


FRESCO was a robust clinical trial that included a population of patients who had received ≥2 prior lines of therapy1,3,4

FRESCO patient characteristics1,3

In a clinical trial, the FRUZAQLA + BSC group (n=278) and Placebo + BSC group (n=138) patient characteristics were well­matched. Key data for the FRUZAQLA vs. Placebo groups includes: median age (55 vs. 57 years); percentage of male patients (56.8% vs. 70.3%); and patients with stage IV cancer at diagnosis (42.1% vs. 45.7%). In both groups, all patients (100%) had prior chemotherapy, and the majority had tumors originating on the left side (77.0% vs. 83.3%) and presented with multiple metastases (95.3% vs.

aMinimum-maximum.4
bAll eligible patients had ECOG PS=0 or 1 (0=fully active, able to carry on all predisease activities without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).2
cReferred to cecum.2
dIncluded 120 patients who had received bevacizumab (fruquintinib arm, 83; placebo arm, 37) and 5 patients who had received aflibercept (fruquintinib arm, 1; placebo arm, 4).2
eCetuximab.2
fNo patients received VEGFR inhibitors.2
 

About 80% of patients in the FRESCO trial received less than or equal to third-line treatment.

FRESCO OVERALL SURVIVAL (OS)

Meaningful time: In a study of FRUZAQLA + BSC vs placebo + BSC in patients with previously treated mCRC, FRUZAQLA demonstrated a significant nearly 3-month improvement in median OS.1

OS in patients with previously treated mCRC

FRESCO: Overall survival (OS) in adult patients with previously treated metastatic colorectal cancer taking FRUZAQLA® + BSC vs placebo. Patients on FRUZAQLA® saw a 34% reduction in risk of disease progression over placebo over 9.3 months.
  • Rapid separation of OS curve beginning at Month 21,2
     

CI=confidence interval; HR=hazard ratio.

35% reduction in risk of death with FRUZAQLA® + BSC vs placebo + BSC.

OS benefit was consistent across most prespecified subgroups2,4 

Results seen regardless of duration of metastatic disease, RAS status, prior types of therapy, and presence of liver metastases

FRESCO: Overall survival (OS) comparing FRUZAQLA® + BSC vs placebo + BSC across prespecified subgroups. FRUZAQLA® had a HR of 0.62 and a 95% CI of 0.49­-0.79. In FRESCO, this was consistent across most subgroups, including patients with a left­-sided primary tumor (HR 0.56, CI 0.43­-0.73), wild­-type K-RAS status (HR 0.56, CI 0.40­-0.78), and those with liver metastases (HR 0.59, CI 0.45­-0.77).

The FRESCO study was not powered to show significance in OS across these specified groups.


FRESCO DISEASE CONTROL

FRUZAQLA improved anti-tumor activity vs placebo1-3

Disease control rate was stable for more than half of patients treated with FRUZAQLA + BSC1,2*

FRESCO: 62% disease control rate with FRUZAQLA® + BSC vs 12% with placebo + BSC.

Complete response and more partial response and stable disease were seen with FRUZAQLA + BSC vs placebo + BSC4

This study was not powered to show significance in disease control rate.

*Disease control was defined as a complete response, partial response, or stable disease for ≥8 weeks.2


FRESCO PROGRESSION-FREE SURVIVAL (PFS)

In a study of FRUZAQLA + BSC vs placebo + BSC in patients with previously treated mCRC

FRUZAQLA more than doubled median progression-free survival1,2

PFS in patients with previously treated mCRC1,2

FRESCO: Progressionfree survival (PFS) in adult patients with previously treated metastatic colorectal cancer taking FRUZAQLA® + BSC vs placebo + BSC. Patients on FRUZAQLA® saw a 74% reduction in risk of disease progression over placebo over 3.7 months.
  • PFS curve had early and rapid separation that was evident at Month 11,2

Statistical significance is not implied. P value for the PFS analysis in FRESCO was not included due to lack of multiplicity adjustment for this analysis.1


Consistent PFS benefit was demonstrated across all prespecified subgroups.2

FRESCO: Progression-free survival (PFS) comparing FRUZAQLA® + BSC vs placebo + BSC across prespecified subgroups. FRUZAQLA® demonstrated a HR of 0.27 and a 95% CI of 0.21­-0.34. This was present across all included subgroups, with particularly strong results in patients with an ECOG performance status of 0 (HR 0.14, CI 0.08­-0.24) and those with wild­-type K-RAS status (HR 0.18, CI 0.13­-0.26).

The FRESCO study was not powered to show significance in PFS across these specified groups.

2L=second-line; 3L=third-line; AR=adverse reaction; BSC=best supportive care; CI=confidence interval; DCR=disease control rate; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; HR=hazard ratio; K-RAS=Kirsten rat sarcoma; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; RAS=rat sarcoma; VEGF=vascular endothelial growth factor; VEGFR=vascular endothelial growth factor receptor.

Loading...

FRUZAQLA patient profiles

Learn about patient types and why they may benefit from FRUZAQLA.

Mechanism of action

Learn how FRUZAQLA works.

Established safety profile

Discover the safety profile of FRUZAQLA from the FRESCO and FRESCO-2 clinical trials.